Adam P Dommer - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Adam P Dommer

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Oncogenesis|April 24, 2026

Cyclin E modulates vulnerability to CDC7 kinase inhibitionAdam P Dommer, Robert Kyne, Jianxin Wang, et al.

Cancer Research|February 13, 2025

Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222Adam P Dommer, Vishnu Kumarasamy, Jianxin Wang, et al.

Nature Communications|February 9, 2025

Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycleVishnu Kumarasamy, Jianxin Wang, Michelle Roti, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Oncogenesis|April 24, 2026

Cyclin E modulates vulnerability to CDC7 kinase inhibitionAdam P Dommer, Robert Kyne, Jianxin Wang, et al.

Cancer Research|February 13, 2025

Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222Adam P Dommer, Vishnu Kumarasamy, Jianxin Wang, et al.

Nature Communications|February 9, 2025

Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycleVishnu Kumarasamy, Jianxin Wang, Michelle Roti, et al.

Pageof 1